What psychiatric manifestations can voriconazole cause?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Psychiatric Manifestations of Voriconazole

Voriconazole commonly causes visual and auditory hallucinations, which are reversible neuropsychiatric adverse effects that occur in approximately 2-3% of patients and are often associated with higher drug concentrations. 1

Primary Psychiatric Manifestations

The most clinically significant psychiatric effects include:

  • Hallucinations (visual and auditory): Reported in 2.4-2.8% of patients in therapeutic trials 1. These can present as vivid visual hallucinations, auditory hallucinations, or both 2, 3, 4, 5

  • Delirium and altered consciousness: Patients may develop confusion, disorientation, and delirium that can be misdiagnosed as postoperative delirium or other causes of encephalopathy 2, 4

  • Disorders of consciousness: Including slow response, restlessness, and agitation 4

Key Clinical Characteristics

Timing and Onset

Psychiatric symptoms typically appear within 1 week of initiating voriconazole therapy 3 and can occur acutely after treatment begins 5.

Concentration-Dependent Toxicity

Hallucinations and neuropsychiatric symptoms are strongly associated with elevated voriconazole trough concentrations, particularly levels >5.0 mg/L 2, 3. The FDA label confirms that toxicity is more common with higher drug levels, though not entirely predictable based on concentration alone 1.

Reversibility

All psychiatric manifestations are reversible upon discontinuation or dose reduction of voriconazole, typically resolving within 4 days of stopping the drug 2, 3, 5.

Mechanism and Risk Factors

The mechanism underlying voriconazole-induced hallucinations remains incompletely understood, though recent evidence suggests dopaminergic modulation may play a role—concomitant use with dopaminergic medications like levodopa significantly increases the risk of visual hallucinations (ROR = 12.3) 6.

Asian populations warrant special attention due to higher prevalence of CYP2C19 poor metabolizers, which leads to reduced voriconazole clearance and increased risk of adverse events 3.

Neurologic Context from Guidelines

The IDSA guidelines 7 emphasize that:

  • Reversible central and peripheral neurologic symptoms and hallucinations occur with significant variability
  • These symptoms may be confused with other CNS dysfunction etiologies including posterior reversible leukoencephalopathy syndrome or calcineurin inhibitor toxicity
  • Voriconazole concentrations are a predictor of CNS neurotoxicity, which is reversible

Clinical Management Algorithm

  1. Recognition: Consider voriconazole as the cause when hallucinations, delirium, or altered consciousness develop within days to weeks of starting therapy

  2. Immediate assessment:

    • Measure voriconazole trough concentration (target therapeutic range 1.0-5.5 mg/L; toxicity risk increases >5.0 mg/L)
    • Rule out alternative causes (metabolic derangements, other medications, CNS infection)
  3. Intervention:

    • If trough >5.0 mg/L or severe symptoms: Discontinue voriconazole immediately 2
    • If moderate symptoms with therapeutic levels: Reduce dose by 50% and recheck concentration
    • Symptoms should resolve within 4 days if voriconazole-related 2
  4. Monitoring: Serial therapeutic drug monitoring is crucial, especially in Asian patients and those on interacting medications 3, 8

Critical Pitfalls to Avoid

  • Do not misattribute symptoms to postoperative delirium, ICU psychosis, or other causes without first checking voriconazole levels and considering temporal relationship 2

  • Do not continue voriconazole at the same dose when psychiatric symptoms emerge—this risks progression to more severe neurotoxicity

  • Route of administration does not influence frequency of these adverse events—both IV and oral formulations carry equal risk 3, 5

  • Be aware that visual disturbances (photopsia, altered color perception) occur in ~21% of patients 1 and may accompany or precede frank hallucinations

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.